市场调查报告书
商品编码
1422062
细胞治疗市场机会与预测(2017-2031):依治疗类型、细胞类型、产品类型、应用、最终使用者和地区Cell Therapy Market Assessment, By Therapy Type, By Cell Type, By Product, By Application, By End-users, By Region, Opportunities and Forecast, 2017-2031F |
全球细胞治疗市场规模预计将从 2023 年的 46.7 亿美元增至 2031 年的 129.3 亿美元,预测期内复合年增长率为 13.56%。
关键驱动因素包括慢性病盛行率上升、研发投资增加、细胞治疗技术持续进步、支持性监管环境、合作关係和扩大应用。 需求增加背后的原因是世界各地慢性病的增加。 随着这些疾病的增加,对创新和有效治疗的需求不断增长,而细胞疗法被定位为一种有前途的解决方案。
慢性病盛行率的上升是全球细胞治疗市场的关键驱动力。 50岁及以上患有至少一种慢性病的人数正在显着增加,预计到2050年将从2020年的7152.2万人增加99.5%,达到1.4266亿。 这种人口结构的变化意味着迫切需要先进且有效的治疗干预措施,而细胞疗法已成为一种有前景的解决方案。 此外,预计患有多种疾病的患者人数将从2020年的783.04万人增加到2050年的1496.8万人,增长91.16%,加剧了老龄化社会面临的健康挑战的复杂性。 为了解决日益增长的健康负担,对创新细胞疗法的需求不断增加,市场定位于应对不断变化的医疗保健格局,并为慢性病管理提供有针对性的解决方案。
各大公司正在建立最先进的生产设施,并对细胞疗法进行重大投资。 这项措施反映了人们对细胞治疗潜力的信心,是全球细胞治疗市场的关键驱动力。 对最先进的製造设施的大量投资将提高生产能力和可扩展性,从而更有效和更广泛地提供基于细胞的疗法。 该行业巨头积极主动地推动创新,促进全球细胞治疗市场的整体成长和成熟,并巩固其作为医疗保健领域变革力量的地位。
世界各国政府正与领先公司合作,促进全球细胞治疗市场的成长。 这些合作伙伴关係旨在利用政府的支持和专业知识来推进细胞疗法的研究、开发和可及性。 透过促进此类合作,政策制定者正在为创新创造有利的环境,加速监管审批,并确保这些先进的医疗干预措施得到广泛采用。 政府和主要行业参与者之间的协同反映了共同承诺,即充分发挥细胞疗法的潜力,彻底改变医疗保健并应对全球范围内的挑战。
本报告调查了全球细胞治疗市场,提供市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司的简介等等。
Global cell therapy market size was valued at USD 4.67 billion in 2023, expected to reach USD 12.93 billion in 2031, with a CAGR of 13.56% for the forecast period between 2024 and 2031. Several factors propel the global cell therapy market, creating an exciting and high-potential environment. Key drivers include the rising prevalence of chronic diseases, increasing investments in research and development, continuous advancements in cell therapy technologies, a supportive regulatory environment, collaborative partnerships, and growing applications. A prominent force behind the growing demand is the increasing prevalence of chronic diseases worldwide. As these conditions become more prevalent, there is an increasing demand for innovative and effective treatments, positioning cell therapy as a promising solution.
Pharmaceutical companies and research institutions are investing significant amounts in exploring the vast potential of cell therapies. This financial commitment fosters groundbreaking discoveries and accelerates the development of novel treatments. Advancements in cell therapy technologies are further contributing to this dynamic landscape. Breakthrough technologies such as CRISPR gene editing are enhancing the precision and efficacy of cell therapies, opening new possibilities for therapeutic interventions across various medical domains in global cell therapy market. A supportive regulatory environment acts as a catalyst, streamlining approval processes and encouraging companies to invest in the development of cell-based treatments, boosting the growth of the global cell therapy market. Collaborative partnerships between pharmaceutical/biotech firms, and academic institutions leverage collective strengths, fostering innovation and expediting the commercialization of promising therapies. As cell therapy applications continue to broaden from oncology to neurodegenerative diseases, the global awareness and acceptance of these innovative treatments are on the rise.
The increasing prevalence of chronic diseases is a significant catalyst for the global cell therapy market. As the population aged 50 and above faces a staggering increase in the incidence of at least one chronic disease, the numbers are projected to surge by 99.5%, reaching 142.66 million by 2050 from 71.522 million in 2020. The demographic shift signifies an urgent need for advanced and effective therapeutic interventions, with cell therapy emerging as a promising solution. Moreover, the projection of a 91.16% increase in individuals with multimorbidity-from 7.8304 million in 2020 to 14.968 million in 2050, highlights the complexity of health challenges an aging population faces. In response to the growing health burden, the demand for innovative cell therapies is rising, positioning the market to address the evolving healthcare landscape and offer targeted solutions for chronic disease management.
Leading companies are investing substantially in cell therapy by establishing state-of-the-art manufacturing facilities. The initiative reflects their confidence in cell therapies' potential and is a significant driver for the global cell therapy market. Significant investments in advanced production facilities enable increasing production capacity and scalability, resulting in a more efficient and widespread delivery of cell-based treatments. The proactive approach by major industry players fosters innovation and contributes to the overall growth and maturity of the global cell therapy market, solidifying their position as a transformative force in healthcare.
For instance, in October 2023, Bayer AG revealed its inaugural cell therapy launch facility in Berkeley, California, marking a pivotal step in their global initiative to provide cell therapies to patients. The USD 250 million, 100,000-square-foot facility is designed to meet the demand for materials in late-stage clinical trials and the potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy under assessment for Parkinson's disease treatment. The establishment of the cutting-edge facility underscores Bayer's commitment to advancing cell therapies on a global scale and signifies a significant investment in the future of innovative medical solutions.
Governments around the globe are collaborating with major companies to stimulate the growth of the global cell therapy market. These partnerships aim to leverage governmental support and expertise to advance research, development, and accessibility of cell therapies. By fostering such collaborations, policymakers seek to create a conducive environment for innovation, accelerate regulatory approvals, and ensure widespread adoption of these advanced medical interventions. The synergy between governments and key industry players reflects a shared commitment to realize the full potential of cell therapies in revolutionizing healthcare and addressing challenges on a global scale.
In September 2023, the United States government unveiled new measures as part of the Cancer Moonshot Initiative, a focal point in the battle against cancer. The initiative was led by President through the collaborative entity "CancerX," aiming to reduce the U.S. cancer death rate by 50% before 2047. The initiative includes prominent pharmaceutical companies and their partnership with digital healthcare solution providers such as Amazon and Intel. The Moffitt Cancer Center in Florida and the Digital Medicine Society (DiMe), a global non-profit of digital medicine experts, lead the effort.
The global cell therapy market is witnessing a growing demand for T-cell therapy. The innovative approach has gained prominence due to its remarkable success in treating certain cancers, especially hematologic malignancies. As clinical trials demonstrate its efficacy and safety, the demand for T-cell therapy is increasing. Patients, healthcare providers, and pharmaceutical companies recognize its potential to revolutionize cancer treatment by leveraging the body's immune system. The increasing demand is propelling research, development, and investment in T-cell therapies, contributing to the dynamic growth of global cell therapy market.
In March 2023, Thermo Fisher Scientific and Arsenal Biosciences, Inc., American companies, announced their strategic partnership to advance the manufacturing processes for novel cancer treatments. The collaboration emphasizes research and process development to establish a robust manufacturing framework for their cutting-edge, programmable autologous T cells designed for cancer treatment.
The global cell therapy market is poised for a promising future, driven by a convergence of factors highlighting its potential to revolutionize healthcare. Advancements in cell therapy technologies, including precision-enhancing techniques like CRISPR gene editing, are increasing the efficacy and scope of treatments. The rising prevalence of chronic diseases, such as cancer and autoimmune disorders, create a compelling need for innovative therapeutic solutions, positioning cell therapy at the forefront of medical breakthroughs. Collaborative partnerships between pharmaceutical companies, biotech firms, and academic institutions are accelerating research and development efforts, fostering a dynamic environment of innovation. Supportive regulatory frameworks and increasing stakeholder awareness contribute towards a favorable landscape for the market's growth. With expanding applications across diverse medical domains and a global commitment to addressing unmet healthcare needs, the cell therapy market is poised to play a pivotal role in shaping the future of healthcare.
Numerous major companies are actively forming collaborations in the global cell therapy market. These strategic partnerships facilitate the pooling of resources, expertise, and technologies to drive innovation and expedite the development of advanced cell-based therapies. By joining forces, these companies enhance their capabilities in research, clinical trials, and manufacturing processes, ultimately contributing to the evolution and expansion of the cell therapy market.
For instance, in August 2023, Astellas Pharma Inc. and Poseida Therapeutics, Inc. unveiled a strategic investment to bolster Poseida's pioneering efforts in redefining cancer cell therapy. In the financial arrangement, Astellas is set to invest a total of USD 50 million, comprising a USD 25 million acquisition of 8,333,333 shares of Poseida's common stock (representing around 8.8% of the total outstanding common stock) at USD 3.00 per share through a private placement. Additionally, a one-time payment of USD 25 million secures Astellas an exclusive negotiation and first refusal right to license Poseida's clinical stage program, P-MUC1C-ALLO1. The program involves the development of an allogeneic CAR-T cell therapy targeting multiple solid tumor indications.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.